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Abstract
The novel antiepileptic drug (R)-N-benzyl 2-acetami-
do-3-methoxypropionamide ((R)-lacosamide, Vimpat
((R)-1)) was recently approved in theUnited States and
Europe for adjuvant treatment of partial-onset seizures
in adults. (R)-1 preferentially enhances slow inactiva-
tion of voltage-gated Naþ currents, a pharmacological
process relevant in the hyperexcitable neuron.We have
advanced a strategy to identify lacosamide binding part-
nersbyattachingaffinitybait (AB) andchemical reporter
(CR) groups to (R)-1 to aid receptor detection and
isolation. We showed that select lacosamide AB and
AB&CR derivatives exhibited excellent activities simi-
lar to (R)-1 in the maximal electroshock seizure model
in rodents. Here, we examined the effect of these
lacosamideABandAB&CRderivatives and compared
them with (R)-1 on Naþ channel function in central
nervous system (CNS) catecholaminergic (CAD) cells.
Using whole-cell patch clamp electrophysiology, we
demonstrated that the test compounds do not affect the
Naþ channel fast inactivation process, that they were
far better modulators of slow inactivation than (R)-1,
and that modulation of the slow inactivation process
was stereospecific. The lacosamideAB agents that con-
tained either an electrophilic isothiocyanate ((R)-5) or
a photolabile azide ((R)-8) unit upon AB activation
gave modest levels of permanent Naþ channel slow
inactivation, providing initial evidence that these com-
poundsmay have covalently reacted with their cognate
receptor(s). Our findings support the further use of
these agents to delineate the (R)-1-mediated Naþ
channel slow inactivation process.
Keywords: Lacosamide, sodium channel, slow inactiva-
tion, affinity bait
E
pilepsy, a major neurological disorder that af-
fects all populations (1), describes the types of
recurrent seizures produced by paroxysmal,
excessive neuronal discharges in the brain (2, 3). The
mainstay of treatment for epileptic disorders has been the
long-termand consistent administrationof anticonvulsant
drugs (4-8).Monotherapy, however, fails for oneof every
two patients with newly diagnosed epilepsy (9, 10). Of
greater importance, currentmedications are ineffective for
approximatelyone-thirdofpatientswith epilepsy (11-14).
Many continue to have seizures, while others experience
disturbing side effects (e.g., drowsiness, dizziness, nausea,
liver damage) (15). The shortcomings of current regimens
highlight theneed for newantiepileptic drugs (AEDs) with
novel mechanisms of action. Unfortunately, the inability
to identify specific nervous system pathways and protein
target sites responsible for seizures and seizure protection
has hampered new drug development.
We discovered the novel AED (R)-N-benzyl 2-acet-
amido-3-methoxypropionamide (16) ((R)-lacosamide,
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(R)-1). (R)-1was recently approved in theUnited States
and Europe for adjuvant treatment of partial-onset sei-
zures in adults (17).We reported on (R)-1 for the control
of convulsive disorders (16), determined the structure-
activity relationship (SAR) of (R)-1 (18, 19), and showed
that anticonvulsant activity for this AED is stereospe-
cific (16, 18). Whole animal pharmacological studies
demonstrated that (R)-1 function is unique and prevents
seizure spread by mechanisms different from current
and emerging clinical agents (20).
Electrophysiology experiments documented that
(R)-1 selectively enhanced slow inactivation of voltage-
gated Naþ channels (VGSCs), a pharmacological site
relevant in the hyperexcitable neuron (21, 22). In neuro-
blastoma cells, (R)-1 enhanced Naþ channel slow in-
activation in a time- and voltage-dependent manner,
without affecting fast inactivation (21). (R)-1 shifted the
slow inactivation voltage curve to more hyperpolar-
ized potentials and enhanced the maximal fraction of
channels that were slowly inactivated. The slow inacti-
vation process by (R)-1 was stereoselective, with (R)-1
being active but (S)-1 not (21). Whole-cell, patch-
clamp electrophysiology was also used to determine
the effects of (R)-1 on recombinant NaV1.3 and
Nav1.7 channels expressed in HEK293 cells and on
NaV1.8-type tetrodotoxin-resistant currents recorded
from small-diameter adult DRG neurons (22). Employ-
ing various (R)-1 concentrations, (R)-1 substantially
reduced Naþ currents and enhanced only the voltage-
dependence of steady-state slow inactivation (22). (R)-1
is the only known AED that selectively enhances slow
inactivation without apparent interaction with fast
inactivation gating (21, 22). Overall, these findings
indicate that (R)-1 reduces pathological activity of neu-
rons (e.g., prolonged depolarizations in the hyperexcit-
able neuron) without disrupting normal physiological
activity.
Wehaveadvancedageneral strategy to identify targets
of (R)-1 function (23). Our approach used compounds
termed (R)-1 AB&CR agents ((R)-2), where AB stands
for affinity bait andCRfor chemical reporter (Figure 1).
TheAB group in (R)-2 permits irreversible adduction of
the modified drug to the receptor to give 3, and the CR
unit allows protein detection and capture upon subse-
quent attachment to a chemical probe (P). Incorporat-
ing AB and CR moieties within the (R)-1 framework
such that neither impedes drug binding to the cognate
receptor(s) is key to this method’s success.
In this study, we examined the effect of 1, 2, and laco-
samide AB derivatives (4) on Naþ channel function in
central nervous system (CNS) catecholaminergic (CAD)
cells (24). We show that CAD cells serve as excellent,
readily accessible surrogates for neuronal cells to exam-
ine drug interactions that affect Naþ channels.We dem-
onstrate that (R)-2 and (R)-4 are more effective than
(R)-1 in selectivelymodulatingNaþ channel slow inacti-
vation processes in CAD cells, thus documenting that
placement of select AB and CRmoieties within the (R)-1
framework did not disrupt the function of these agents.
Figure 1. Use of theAB&CR strategy to identify potential drug receptors. Scheme showing the binding of lacosamideAB&CR (2) to a putative
receptor. Initial binding provides a complex that permits covalent adduction through theABmoiety to give 3. Protein detection is accomplished
by reacting with a fluorescent probe containing an azide moiety by Cu(I)-mediated cycloaddition. Correspondingly, reacting 3 with a
biotinylated probe containing an azide moiety allows receptor isolation using streptavidin.
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We further report thatmodulation ofNaþ channel slow
inactivation by these agents is stereospecific and that the
level of stereospecificity is similar to that observed in
whole animal, behavioral seizure models (16, 18). CAD
cells treated with 4 under conditions that led to AB




Eight compounds were selected for study in CAD
cells. (R)-1 and its stereoisomer, (S)-1, served as the
parent compounds. We compared (R)-1 and (S)-1 on
CAD cell sodium channel functionwith previous results
obtained in neuroblastoma cells (21). Next, we selected
three (R)-4 agents wherein the AB moiety was incorpo-
rated at the benzyl amide 40-site ((R)-5-(R)-7) (Table 1).
We have reported that 40-aryl substitution of (R)-1 pro-
vided compoundswith exceptional anticonvulsant activity
in the maximal electroshock (MES) seizure model(25) in
rodents but that structural constraints for maximal activ-
ity existed for this substituent (18). Electrophilic (isothio-
cyanate (R)-5)(25) and photolabile (azide (R)-6 (26),
(trifluoromethyl)diazirine (R)-7) AB groups were eval-
uated. BothAB types have been used in targetmodifica-
tion studies (27-31). We included the (R)-1 AB&CR
agent, (R)-8, in which the AB group was an isothiocya-
nate and the CR group was an alkyne unit. We have
reported that replacing the 3-methoxy group in (R)-1
Table 1. Anticonvulsant and Patch Clamp Electrophysiology Data for Lacosamide, Lacosamide-AB, and
Lacosamide AB&CR Agents
aThe compounds were administered intraperitoneally. ED50 and TD50 values are in milligrams per kilogram. Numbers in parentheses are 95%
confidence intervals. The dose effect was obtained at the time of peak effect (indicated in hours in brackets). bMES=maximal electroshock seizure
test. cTD50 value determined from the rotorod test.
dThe compounds were administered orally. ED50 and TD50 values are in milligrams per
kilogram. eTox = behavioral toxicity. f IC50, Concentration at which half of the Na
þ channels have transitioned to a slow inactivated state.
gReference 16. hReference 25. iReference 26. jND, not determined. kReference 41. lNo ataxia observed up to 3000 mg/kg. mNS, not selective for
slow inactivation. nReferences 21 and 57.
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withapropargyloxymoiety provideda lacosamidederiv-
ative with excellent activity in theMES test (19, 25, 26).
Moreover, the alkyne group in (R)-8 readily undergoes
[3 þ 2] copper(I)-mediated cycloaddition with azide
probes (click chemistry) (31-34). For compounds 1, 5,
and 8, we also tested the corresponding stereoisomer.
Synthesis
Wehave reported the stereospecific syntheses of 1 (16),
5 (35), 6 (26), and 8 (25). Compound 7 was prepared by
coupling (R)-2-acetamido-3-methoxypropionoic acid(36)
(9) with4-[3-(trifluoromethyl)-3H-diazirin-3-yl]-benzene-
methanamine (10)(37) using 4-(4,6-dimethoxy-1,3,5-tria-
zin-2-yl)-4-methoxymorpholinium chloride (DMTMM)
(38) (Scheme 1). The enantiopurity of (R)-7 was deter-
mined with the chiral-resolving agent (-)-mandelic
acid (39).
Whole Animal Pharmacological Activity
Compounds (R)-1, (S)-1, (R)-5, (S)-5, (R)-6, (R)-7,
(R)-8, and (S)-8 were tested for anticonvulsant activity
at the Anticonvulsant Screening Program (ASP) at the
National Institute ofNeurological Disorders and Stroke
(NINDS),U.S.National Institutes ofHealth. Screening
wasperformedusing the procedures describedbyStables
and Kupferberg (40). The pharmacological data from
theMES test(24) are summarized inTable 1, and similar
results were obtained for the clinical AEDs pheny-
toin (41), valproate (41), and phenobarbital (41). All com-
pounds were administered intraperitoneally (ip) to mice
and orally (po) to rats. Table 1 lists the values from the
rodent identification studies determined to be protective
in blocking hind limb extension induced in the MES
seizure model. For compounds that showed significant
activity, we report the 50% effective dose (ED50) values
obtained in quantitative screening evaluations.Also pro-
vided are the median doses for 50% neurological im-
pairment (TD50) inmice, using the rotorod test (42), and
the behavioral toxicity effects observed in rats (43).
TD50 values were determined for those compounds that
exhibited significant activity in the MES test. When the
lacosamide derivatives were evaluated in the subcuta-
neous Metrazol (scMet) seizure model(44), none pro-
vided protection at doses up to 300 mg/kg at two time
points (0.5 and 4 h) (data not shown). The absence of
seizure protection in this assay is a hallmark of this class
of compounds (16, 18, 19).
Compounds 1 and 5-8 all exhibited pronounced
seizure protection in the MES test in both mice (ip)
and rats (po) when the stereochemical configuration of
the C(2) chiral center corresponded to the D-amino acid
((R)-configuration). In mice, we observed a 2-10-fold
loss of activity comparedwith (R)-1 upon incorporation
of either an AB moiety (4-7) or both an AB and CR
group (8) (16).While thewhole animal pharmacological
data do not permit us to identify the factors (e.g., effec-
tiveness of the agent, metabolic factors, CNS bioavail-
ability) that contributed to the modest loss of anti-
convulsant activity, we found that incorporating theAB
and CR moieties did not markedly alter the activity of
these compounds in theMES test or the requirement for
the D-amino acid configuration for activity seen for
1 (16).
Lacosamide Derivatives Inhibit Naþ Currents
Using the whole-cell patch clamp configuration, the
effects of (R)-1 and its derivatives, (R)-5-(R)-8, on
voltage-gated Naþ channels were examined in CAD
cells. CAD cells were chosen because they have a neu-
ronal origin and express endogenous tetrodotoxin-
sensitive Naþ currents with rapid activation and inactiva-
tion uponmembrane depolarization (45, 46). Real-time
quantitativePCR (qRT-PCR) ofCADcells revealed the
presence of relatively high levels of NaV1.7 mRNA
(Figure 2, Table 2). Compared with NaV1.7, lower
levels of NaV1.1, NaV1.3, and NaV1.9 mRNAs were
also detected while isoforms NaV1.2, NaV1.4, NaV1.5,
Scheme 1. Synthesis of (R)-7
Figure 2. Quantitative RT-PCR for the indicated NaV1.x genes
from CAD cells. mRNAs for Naþ channel isoforms NaV1.1, 1.3,
1.7, and 1.9 were detected from CAD cells. Data are expressed as
percent of L27 mRNA (a ribosomal internal control gene) ( SEM
(n = 6 for each).
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and NaV1.8 were either at very low or undetectable
levels. Due to lack of available antibodies against the
various isoforms, we were unable to determine the
relative contribution of the various proteins to the
Naþ currents in these cells. However, consistent with
previous findings, in preliminary recordings, we ob-
served that almost all of the current was blocked with
500 nM tetrodotoxin, suggesting that most of the Naþ
current is likely contributed by NaV1.7, NaV1.1, and
NaV1.3 (data not shown).
In the initial set of experiments, the ability of 100 μM
(R)-1, (S)-1, and lacosamide derivatives to inhibit peak
inward Naþ currents was tested by holding CAD cells
at -80 mV and running a current-voltage (I-V) pro-
tocol,which consistedof 15ms stepdepolarizations rang-
ing from -70 to þ80 mV (in þ10 mV increments)
(Figure 3A, inset). Figure 3A shows an I-V family of
Naþ currents recorded from CAD cells treated with
0.1% dimethyl sulfoxide (DMSO) (predrug control),
100 μM (R)-5, or 100 μM (S)-5. The transient inward
current inCADcells activatedbetween-40 and-30mV
and reached its peak at 0 to þ10 mV (Figure 3B). Peak
inward Naþ currents elicited at each step were plotted
with respect to voltage. The peak currents were normal-
ized by cell capacitance and expressed as peak current
density (pA/pF) to account for variations in cell size.
CAD cells treated with 0.1%DMSO (vehicle) exhibited
a peak current density of-43.7( 6.7 pA/pF (n= 28).
(R)-1 reduced the peak current by 40%, similar to our
recently published findings (46), while the inactive
enantiomer (S)-1 exhibited no inhibition (Figure 3C).
Lacosamide derivatives (R)-5 and (R)-8 reducedpeak
Naþ currents by almost 95%, while (R)-6 reduced cur-
rents by about 40%, similar to (R)-1.While (S)-8 hadno
effect on peak Naþ currents, the inactive enantiomer
(S)-5 also inhibited peak currents elicited fromaholding
potential of -80 mV by about 60%. Inhibition of Naþ
currents was not accompanied by changes in reversal
potential, half-maximal activation, or slope parameters
(see Figure 6) for any of the lacosamide derivatives.
Lacosamide Derivatives Affect the Transition to
a Slow Inactivated State ofNaþCurrents inCAD
Cells
(R)-1 has been demonstrated to reduce VGSC avail-
ability by selectively enhancing the transition to a slow-
inactivated state of VGSCs (21, 22, 46). Therefore, we
tested the ability of lacosamide derivatives to modulate
transition to a slow-inactivated state inCADcells. CAD
Table 2. Primers Used for Amplification of Nav1.1-9 Isoforms from CAD Cells
gene primer sequence (forward-reverse)
L27 GGTCATCGTGAAGAACATTG-CATGGCAGCTGTCACTTTC
NaV 1.1 AGAGGGAAGTTGGGATTGATG-TGGTGATTTGGAACAGGCAG








Figure 3. Inhibition of Naþ currents by lacosamide derivatives. (A)
Representative families of current responses of CAD cells treated
with 0.1% DMSO control (predrug), 100 μM (R)-5, or 100 μM
(S)-5. The voltage protocol used to evoke theNaþ currents is shown
in the boxed inset. (B) Summary of current-voltage (I-V) rela-
tionships for CAD cells treated with the compounds illustrated in
(A) (n = 8 each). (C) Peak current density (pA/pF) measured at
0 mV for CAD cells treated with control (n = 9) or all lacosamide
derivatives (100 μM each; n > 7 for each condition). *, p < 0.05
versus control or the respective (S)-isomer.
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cells were held at-80mV and conditioned to potentials
ranging from-120 toþ20 mV (inþ10 mV increments)
for 5 s. Then fast-inactivated channels were allowed to
recover for 150msat a hyperpolarizedpulse to-120mV,
and the fraction of channels available was tested by a
single depolarizing pulse, to 0mV, for 15ms (Figure 4A,
inset). The brief hyperpolarizationwas used to allow the
channels to recover from fast inactivationwhile limiting
recovery from slow inactivation.
A representative family of slow inactivation traces
from CAD cells treated with 0.1% DMSO or 100 μM
(R)-1, (R)-5-(R)-8, (S)-1, (S)-5, and (S)-8 are shown in
Figure 4A.For comparison, representative current traces
at -50 mV are highlighted. This potential (-50 mV)
was chosen for three reasons: (1) a majority of chan-
nels are undergoing steady-state inactivation, which
involves contributions from slow and fast inactivating
pathways(47, 48) where -50 mV is within the steep
voltage-dependence range for each, (2) it is near the
resting membrane potential (RMP) and approaching
the action potential firing threshold for CNS neu-
rons (49), where slow inactivation appears to be phy-
siologically relevant during prolonged subthreshold
depolarizations (50), and (3) changes in theNaþ channel
availability near-50mV can impact the overlap ofNaþ
current activating and inactivating under steady-state
conditions (48, 51). Adding 100 μM (R)-1 to CAD cells
significantly decreased the fraction of current available
compared with cells without (R)-1. (S)-1 did not reduce
the available current (compare -50 mV traces in all
families). At-50 mV, 0.35( 0.01 fractional units (n=
9) of the Naþ current were available, suggesting a large
fraction (i.e., 0.65 ( 0.08; calculated as 1 minus the
normalized INa) of the channels transitioned to a
nonconducting (slow-inactivated) state in (R)-1-treated
cells (Figure 3B, C). These findings are consistent with
Figure 4. Enantioselective effect of steady-state slow inactivation state of Naþ currents in CAD cells by lacosamide, lacosamide AB, and
lacosamide AB&CR compounds. (A) Currents were evoked by 5 s prepulses between -120 and þ20 mV, and then fast-inactivated channels
were allowed to recover for 150 ms at a hyperpolarized pulse to -120 mV. The fraction of channels available at 0 mV was analyzed.
Representative current traces from CAD cells in the absence (control, 0.1% DMSO) or presence of 100 μM of compounds as indicated. The
black (control) and color (all others) traces in each panel represent the current at -50 mV (also highlighted in the voltage protocol). (B)
Summary of steady-state slow activation curves for CAD cells treated with DMSO (control) or 100 μM of the indicated compounds. Drug-
induced slow inactivation was most prominent in CAD cells treated with (R)-5 and (R)-8 compounds. (C) Summary of the fraction of current
available at -50 mV for CAD cells in the absence or presence of (R)- or (S)-enantiomers of the indicated compounds. Asterisks (*) indicate
statistically significant differences in fraction of current available between (R)- and (S)- compounds (p<0. 05, Student’s t test). Hashmarks (#)
indicate a statistically significant difference in fraction of current available between control and all other conditions tested (p<0.05, Student’s
t test). Data are from 7-12 cells per condition.
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earlier results that showed that (R)-1, but not (S)-1,
modulatedNaþ channel slow inactivation in neuroblas-
toma cells(21) and that (R)-1 promoted slow inactiva-
tion in recombinant hNaV1.7 channels expressed in
HEK cells (22). The similarity of our data with these
earlier findings supported our use of CAD cells to
elucidate the effects of the lacosamide derivatives on
Naþ channel function.
Using this patch-clamp protocol, physiological slow
inactivation was observed at potentials more depolar-
ized than-100 mV for (R)-5 and (R)-8 or at potentials
more depolarized than -80 mV for (R)-1 and (R)-6
(Figure 4B). Comparedwith (R)-1, both (R)-5 and (R)-8
caused a significant increase in the maximal fraction of
current unavailable by depolarization (20 mV; control,
0.62( 0.03, n=8; (R)-1, 0.26( 0.01, n=9; (R)-5, 0.02
( 0.03, n = 8; (R)-8, 0.07 ( 0.01, n = 9; p < 0.01,
Mann-WhitneyU test). Almost all (0.95( 0.01; n=8)
channels of (R)-5-treated cells were in a slow-inactivated
state, while only 0.35( 0.09 (n= 8) of its stereoisomer
(S)-5 Naþ channels were. (R)-8 also had a similar
enantioselective effect to the (S)-8 stereoisomer, with
0.90 ( 0.02 (n = 8) and 0.45 ( 0.08 (n = 9) of the
channels in a slow-inactivated state, respectively. Both
(R)-6 and (R)-7had slow-inactivated fractions similar to
(R)-1: 0.68 ( 0.07 (n = 8) and 0.66 ( 0.05 (n= 8).
To better understand the interaction among lacosa-
mide derivatives and the extent to which they induce
slow inactivation, weperformed concentration response
curves for slow inactivation induction for eachcompound.
An example of the concentration response for slow
inactivation induced by 0.1-100 μM (R)-5 is shown in
Figure 5A.Fits of the concentration responseof slow inac-
tivation against the V1/2 of slow inactivation provide a
50% inhibitory concentration (IC50) value of 8.1 μM
(Figure 5B). Table 1 shows the IC50 values for slow inac-
tivation induced by the other lacosamide derivatives.
Compared with the IC50 value of 85 μM estimated for
the slow inactivation induced by (R)-1, the IC50 value
for (R)-7 was 7.1-fold lower while (R)-8 was 5.3-fold
lower. In all cases, the IC50 value for slow inactiva-
tion was lower for the (R)-stereoisomer versus the (S)-
enantiomer.
Collectively, these data indicate that lacosamide
derivatives (R)-5-(R)-8 are more effective at inducing
the transition of Naþ channels to a slow-inactivated state
than the parent (R)-1, and lacosamide compounds (R)-1,
(R)-5, and (R)-8modulate Naþ channel slow inactivation
in an enantioselective fashion.While the enhanced activ-
ity (lower IC50 values) observed for the (R)-2 (i.e., (R)-8)
and the (R)-4 (i.e., (R)-5-(R)-7) derivatives compared
with (R)-1 is significant, we are uncertain to attribute
specific structural and physiochemical properties (e.g.,
size, lipophilicity) to the decreased IC50 values for the
lacosamide AB and AB&CR agents. Nonetheless, the
calculated log P values (ACDLabs software) for the
(R)-2 and (R)-4 derivatives (1.14-2.42) were higher
than that for (R)-1 (0.73), suggesting that these agents
aremore lipophilic than (R)-1 and are therefore likely to
achieve higher intracellular concentrations under the
conditions we are using. It is also possible that these
structural modifications increase the interaction be-
tween lacosamide derivatives and their receptor(s). The
much lower IC50 values observed for (R)-2 and the (R)-4
derivatives compared with (R)-1might be due to a com-




Are Not Affected by Lacosamide Derivatives
Becausechanges incurrentamplitudes couldresult from
changes in channel gating (52), we tested if lacosamide
Figure 5. Concentration response curve for (R)-5 on the induction
of Naþ currents slow inactivation. (A) Summary of steady-state
slow activation curves for CAD cells treated with DMSO (0) or
0.1-100 μM(R)-5. Each curve was fit with a Boltzmann equation to
yield values for V1/2, the voltage of half-maximal inactivation. (B)
Concentration versus V1/2 response curve for effects on slow
inactivation. To estimate the half-maximal value for induction of
slow inactivation, dose-response curveswere fit using the equation:
Y = A1 þ (A2 - A1)/(1 þ 10(log X0 - x)p), where Y is the measured
response of the INa, A2 and A1 are the maximum and minimum
responses, respectively, of the INa obtained with a control sample, p
is the slope parameter of the dose-response curve, x is the applied
dose, and log X0 is the center of the curve that is the concentration
for half the INa response. The curves were well-fitted with this
dose-response function (R2 > 0.91). Each point is the mean (
SEMof 6-9CADcell recordings. The half-maximal values for slow
inactivation for the rest of the compounds are shown in Table 1.
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derivatives altered the voltage-dependent activation pro-
perties of Naþ currents in CAD cells. Changes in acti-
vation for the CAD cells treated with the derivatives
weremeasuredbywhole-cell ionic conductances by com-
paring their respective midpoints (V1/2) and slope fac-
tors (k) in response to changes in command voltage
(Figure 6A). An analysis of all V1/2 (Figure 6B) and k
(Figure 6C) values showed that therewere no changes in
the steady-state activation properties of Naþ currents
between CAD cells treated with DMSO control or with
any of the lacosamide derivatives. These data indicate
that lacosamide derivatives do not affect the channel’s




Cells Are Not Affected by Lacosamide Derivatives
Our data indicated that (R)-1 and lacosamide deri-
vatives (R)-5-(R)-8 exhibit preferential effects on the
slow inactivated state ofNaþ channels.We asked if (R)-
1 and its derivatives could enhance steady-state fast inac-
tivation. For this, we used a protocol (see Figure 7) de-
signed toaccumulate channels ina fast-inactivated state,
as previously described (28). Cells were held at-80mV,
stepped to inactivating prepulse potentials ranging
from-120 to-10mV (in 10mV increments) for 500ms,
and then the cells were stepped to 0 mV for 20 ms to
measure theavailable current.A500ms conditioningpulse
was used because it allows all of the endogenous channels
to transition to a fast-inactivated state at all potentials
Figure 6. Activation properties of Naþ currents are not affected by
lacosamide, lacosamide AB, and lacosamide AB&CR compounds
in CAD cells. Values for V1/2, the voltage of half-maximal activa-
tion, and the slope factors (k) were derived from Boltzmann
distribution fits to the individual recordings and averaged to
determine the mean ((SEM) voltage dependence of activation. The
voltage protocol used to evoke current responses is shown in
Figure 2A. Representative Boltzmann fits for DMSO, 100 μM
(R)-8, and 100 μM (S)-8 are shown (A). The V1/2 (B) and k (C) of
activation were not different among any of the compounds tested
(p>0.05, one-way ANOVA). Data are from 7-12 cells per condition.
Figure 7. Fast inactivation properties of Naþ currents are not
affected by lacosamide, lacosamide AB, and lacosamide AB&CR
compounds inCADcells. (A)Voltage protocol for fast inactivation.
Representative current traces showing voltage-dependent fast
inactivation of Naþ currents from CAD cells treated with 0.1%
DMSO control (black traces), 100 μM (R)-6 (green traces), or
100 μM (R)-7 (purple traces). Values for V1/2, the voltage of half-
maximal inactivation, and the slope factors (k) were derived from
Boltzmann distribution fits to the individual recordings and aver-
aged to determine the mean ((SEM) voltage dependence of steady-
state inactivation. The V1/2 (B) and k (C) of steady-state fast
inactivation were not different among any of the conditions tested
(p> 0.05, one-way ANOVA), with the exception of the k of (R)-7,
which was significantly different from all other conditions
(p < 0.05, one-way ANOVA).
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assayed. To negate any possible effects of time-dependent
shifts in the voltage dependence of fast inactivation, com-
parisons were made on data obtained 3-4 min after
establishing thewhole-cell recording configuration from
cells in the absence of drugwith similar data obtained in
the presence of the lacosamide derivatives. Steady-state,
fast inactivation curves of Naþ currents from DMSO-,
(R)-1-, (S)-1-, (R)-5-(R)-8-, (S)-5-, and(S)-8-treatedCAD
cells were well fitted with a single Boltzmann function
(R2 > 0.9987 for all conditions). The V1/2 value for
inactivation for 0.1%DMSO-treated cells was-67.5(
1.0 mV (n = 8), which was not different from that of
(R)-1-treated cells (-69.5( 1.3mV; n=9; p>0.05; see
Figure 7B). No statistically significant shifts in the
voltage-dependence of fast inactivation were observed
for anyof the (R)-5-(R)-8or (S)-5and (S)-8 compounds
(see Figure 7B). Neither were the slopes (k) of the fast
inactivation curves affected by lacosamide derivatives
(see Figure 7C), with the exception of (R)-7, which had a
slope that was about 55% shallower than that of cells
treated with DMSO (p< 0.05, see Figure 7C).
Frequency-Dependent Block of Na
þ
Currents
by Lacosamide and AB Agent (R)-5 on CAD
Cells
We selected (R)-1, (S)-1, (R)-5, and (S)-5 to study the
frequency-dependent block (and development of inhibi-
tion/slow inactivation; see next section) ofNaþ currents
by lacosamide and lacosamide analogues. (R)-1 and
(S)-1, its inactive isomer, served as controls, while (R)-
5 is themost active lacosamideagentwe evaluated in this
study and (S)-5 is its corresponding isomer. Block of
Naþ currents in an activity- or use-dependent manner is
a useful property for antiepileptic drugs, since it allows
for preferential decreases in Naþ channel availability dur-
ing high-frequency (i.e., seizures) but not low-frequency
firing. Thus, we next tested if (R)-1 (100 μM), (S)-1
(100μM), (R)-5 (15μM), and (S)-5 (100 μM) could elicit
use-dependent block. A train of 30 test pulses (20 ms
to -10 mV) was delivered from a holding potential
of -80 mV at 10 Hz. The available current in control
and in the presence of drug agents was calculated by
dividing the peak current at any given pulse (pulseN) by
the peak current in response to the initial pulse (pulse1).
Both (R)-1 and (R)-5 reduced current amplitude com-
paredwith control (Figure 8C). Blockwas also observed
with (S)-5; this was likely due to the high (100 μM)
concentration used. In contrast, (S)-1 did not elicit any
use-dependenceblock at the concentration tested.While
use-dependent block by (R)-1 was first observed by
about the 19thpulse in the train, (R)-5didnot showsuch
latency with rapid block seen as early as pulse 8
(Figure 8C, arrow). By the last pulse, compared to con-
trol, the peak currentwas∼10% lower in the presence of
(R)-1and30%lower in thepresenceof (R)-5 (Figure 8C).
The isothiocyanate lacosamide AB agent (R)-5, despite
being used at 15 μM in these experiments, was about
Figure 8. Effects of frequency-dependent block by lacosamide and the isothiocyanate lacosamide AB agent (R)-5 on Naþ currents in CAD
cells. (A) The frequency dependence of block was examined by holding cells at a hyperpolarized potential of-80 mV and evoking currents at
10 Hz by 20 ms test pulses to -10 mV. (B) Representative overlaid traces are illustrated of the 1st, 10th, 20th, and 30th pulses for control
(predrug) and in the presence of (R)-1 (100 μM) and (R)-5 (15 μM). (C) Plot summarizing the average frequency-dependent decrease in current
amplitude ((SEM) produced by (R)-1 and (R)-5 but not by control conditions (for clarity the use-dependence of the (S)-enantiomers is not
shown). (D) Summary of the maximal decrement in current amplitude observed at the end of the 30 pulse train for control, (R)-1, (S)-1, (R)-5,
and (S)-5. (R)-1, (R)-5, and (S)-5 caused a significant decrease in current amplitude compared with pretreatment (*, p < 0.05, one-way
ANOVAwithDunnett’s posthoc test). Note the rapid frequency-dependent facilitation of block by (R)-5 that was observed beginning as early
as pulse 8 (arrow). Data are from 5-6 cells per condition.
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25% more effective in facilitating use-dependent block
of Naþ currents.
Rate of Development of Inhibition/Slow
Inactivation Is Altered by Lacosamide and
AB Agent (R)-5 on CAD Cells
Tounderstand the interaction between (R)-1 and (R)-
5 and Naþ channels, we next investigated the time
course of development of block by these agents and
their enantiomers. Development of block was examined
by holding the cells at -120 mV in the absence or
presence of (R)-1 (100 μM), (S)-1 (100 μM), (R)-5
(15 μM), and (S)-1 (100 μM), prepulsing the cells to
0 mV for varying amounts of time to allow block to
develop, hyperpolarizing the cells to-120mV for 20ms
to allow unbound channels to recover from fast
inactivation, then stepping the cells to 0 mV for 20
ms to determine the fraction of channels available for
activation (Figure 9A). The reduction in the fraction
of current available is indicative of the time course
for the development of slow inactivation. The time
course of reduction in channel availability without
drug as well as in the presence of (R)-1 and (R)-5 was
biphasic, with a fast component likely representing
development of block of fast-inactivated channels and a
slow component that was consistent with the time course
of development of slow inactivation (Figure 9B). The time
constant for development of block was ∼1.5-fold
faster in cells treated with (R)-1 (100 μM) or (R)-5
(15 μM) compared to vehicle-treated cells. Both (S)-1
and (S)-5 enantiomers caused a reduction in the
fraction of current at 8 s (Figure 9, inset box) that
trended toward a difference from the (R)-enantiomers
but was not statistically significant. At this point, we
are not sure of why stereospecificity is not observed
for these drugs in this particular protocol.
Select Lacosamide Derivatives May Irreversibly
Affect the Transition to a Slow-Inactivated State
of Na
þ
Currents in CAD Cells
If either lacosamide AB ((R)-4) or lacosamide AB&
CR ((R)-2) irreversibly affects Naþ channel slow inacti-
vation by covalently modifying a receptor that affects
this process, then slow inactivation should still be ob-
served when the drug derivative is removed from the
CAD cells by extensive washing with an extracellular
bath solution. Alternatively, if either (R)-1, (R)-2, or
(R)-4 reversibly modify Naþ channel slow inactivation
by a noncovalent interaction, then slow inactivationwill
be lost when the lacosamide derivative is removed by
washing. Todistinguish these possibilities, we compared
the effects of (R)-1with the electrophilic AB agent, (R)-
5, and the photolabile AB agents, (R)-6 and (R)-7, on
Naþ channel inactivation using conditions designed to
activate the AB group.
In the initial series of experiments,wedetermined that
CAD cells treated with 0.1% DMSO (control) had
about 10% (at -50 mV) of their Naþ channels in a
slow-inactivated fraction (Figures 3B, 9, and10), a value
that was not different if the cells were subsequently
washed for 5 min or longer with an extracellular bath
solution (datanot shown).Next,we compared the extent
of Naþ channel slow inactivation induced in CAD cells
upon 10 min incubation with 100 μM (R)-1 or 40 μM
(R)-5 followed by a 5 min wash period with fresh
extracellular bath solution.Weexpected that incubation
of theCADcells with (R)-5 at 37 C for 10minwould be
sufficient to lead to (some) irreversible adduction of a
receptor, provided binding was modest and a nucleo-
phile was positioned near the isothiocyanate group
(23, 26). The slow inactivation curves in the absence,
presence, or following washout of these agents are
shown in Figure 10A, G, and Figure 10B, H illustrates
the extent of slow inactivation at -50 mV under these
conditions.Weobserved that the effect of (R)-1was com-
pletely reversed following the 5min wash, while for (R)-
5 a small but significant fraction (∼10%) of the channels
remained in a slow-inactivated state after the CAD cells
were washed. The apparent modest irreversibility in
Figure 9. Rate of development of inhibition/slow inactivation is
altered by lacosamide and the isothiocyanate lacosamide AB agent
(R)-5 in CAD cells. (A) Voltage protocol for development of
inhibition/slow inactivation. Following a variable conditioning
pulse to 0 mV, a 20 ms pulse to-120 mV allows recovery from fast
inactivation (but not block) before the fraction of current available
with the 20-ms pulse to 0 mV. (B) (R)-1 increased the rate of
development of inactivation/inhibition compared to that observed
in vehicle-treated CAD cells at prepulse durations greater than 2 s.
For (R)-5, this increase occurred at prepusle durations longer than
512 ms (p < 0.05, one-way ANOVA with Dunnett’s postdoc test).
Inset: The fraction of current available at 8 s (arrow) prepulse
duration was significantly smaller for (R)-5 (0.18 ( 0.009, n = 6),
(R)-1 (0.31( 0.01, n=6), its inactive isomer (S)-1 (0.35( 0.03, n=
6), and (S)-5 (0.26 ( 0.08, n= 5) compared to vehicle-treated cells
(0.51 ( 0.08, n = 6; p < 0.05, one-way ANOVA with Dunnett’s
postdoc test).
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slow inactivation for (R)-5wasnot due to any changes in
steady-state activation or fast inactivation, as these
values were not different in predrug, drug, or washout
conditions (Figure 10I-L). However, we observed no
appreciable changes in the current amplitudes after the
CAD cells were washed. The current amplitudes at-10
mV, a voltage at which Naþ channel activation is linear
and slow inactivation has reached steady state, recov-
ered by 74% and 72% for (R)-1 and (R)-5, respectively,
compared with predrug values. Thus, the data only
suggest that (R)-5 modified the receptor(s) responsible
for Naþ channel slow inactivation.
Since the photolabile agents, (R)-6 and (R)-7, were
bettermodulators ofNaþ channel slow inactivation than
(R)-1, we next tested their effects in CAD cells upon
activation.Accordingly, the CAD cells containing (R)-6
were irradiated with ultraviolet light (312 nm) for 5 min
using a hand-held UV transilluminator (26). The frac-
tion of channels in the slow-inactivated state was similar
in cells exposed to DMSO control (predrug) and UV
alone treatments (Figure 11A-C). For the (R)-6 UV-
treated cells,∼45%of the channels had transitioned to a
slow-inactivated state, a value that was not signifi-
cantly different from the 50% of channels in the slow-
inactivated state in nonirradiated cells exposed to (R)-6
(Figure 11A-C). Importantly, for cells treatedwith (R)-
6, exposed toUV irradiation and thenwashed for 5min,
about 20% of Naþ channels remained in a slow-inacti-
vated state comparedwith∼10%of channels in the slow-
inactivated state in cells exposed toUV irradiation alone
(Figure 11B, C). This increase in the percentage of
Naþ channels in the slow-inactivated state may indi-
cate that a small fraction of the receptors responsible for
this phenomenon have been covalently adducted by
Figure 10. Effects of lacosamide and the isothiocyanate lacosamide AB agent (R)-5 onNaþ currents slow inactivation in CAD cells. Summary
of steady-state slow activation curves forCADcells treated for 10min at 37 CwithDMSOcontrol (predrug), 100μM(R)-1 (A), or 40μM(R)-5
(G), or they were treated with 100 μM(R)-1 (A) or 40 μM(R)-5 (G) and washed with complete medium (seeMethods) for 5 min. Currents were
evoked as described in the legend to Figure 1. Numbers of cells are indicated in parentheses (n). (B, H) Summary of the fraction of current
available at -50 mV for CAD cells in the absence or presence of the indicated drug conditions. Asterisks (*) indicate statistically significant
differences in fraction of current available between either (R)-1 or (R)-5 and predrug values or between (R)-1 or (R)-5 and washout values (p<
0. 05, Student’s t-test). Hash marks (#, H) indicate a statistically significant difference in fraction of current available at -50 mV between
predrug and washout values (p<0. 05, Student’s t test). Data are from 7-12 cells per condition. TheV1/2 (C, I) and k (D, J) of activation were
not different among any of the conditions tested (p > 0.05, one-way ANOVA). Similarly, the V1/2 (E, K) and k (F, L) of steady-state fast
inactivation were not different among any of the conditions tested (p > 0.05, one-way ANOVA).
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photoactivated (R)-6. The current amplitudes at-10mV
recovered by 79% in cells treated with (R)-6, exposed to
UV irradiation, and then washed for 5 min compared
with predrug values, and by 75% compared with the
UV-treated cells that had not been treated with (R)-6.
There were no changes in steady-state activation or fast
inactivation between any of the conditions tested
(Figure 11D-G).
Photoactivation of (R)-7 in CAD cells was achieved
by exposing (R)-7-treated cells to sequential irradiation
at 365 nm for 8 min followed by 312 nm for 1 min (53).
The fraction of channels in the slow-inactivated state
were similar in cells exposed toDMSOcontrol (predrug)
andUV irradiationalone treatments.When the cellswere
treated with (R)-7 and then photoactivated, about 35%
of Naþ channels were observed to accumulate in the
slow-inactivated state compared with 65% in (R)-7-
treated cells without light (Figure 11I, J).We tentatively
attribute the loss of (R)-7 activity to the photodegrada-
tion of the (trifluoromethyl)diazirine moiety leading to
an inactive agent. In cells treated with (R)-7, exposed to
UV irradiation, and then washed for 5 min, about 10%
Figure 11. Effects of the azido lacosamide AB agent (R)-6 and 3-(trifluoromethyl)-3H-diazirinyl-3-yl lacosamide AB agent (R)-7 on Naþ
current slow inactivation in CAD cells. Summary of steady-state slow activation curves for CAD cells treated with DMSO control (predrug),
40 μM (R)-6 (A, B), or 30 μM (R)-7 (H, I), or they were UV irradiated in the presence or absence of the indicated drugs. The experiments were
repeated and followed by a 5min wash with complete medium, as described inMethods. CAD cells were exposed to a photoactivation regimen
of irradiation at 312 nm for 5 min (in the absence or presence of (R)-6) or sequential irradiation at 365 nm for 8 min followed by irradiation at
312 nm for 1 min (in the absence or presence of (R)-7). (C, J) Summary of the fraction of current available at -50 mV for CAD cells in the
absence or presence of the indicated drug and UV conditions. Asterisks (*) indicate statistically significant differences in fraction of current
available between (R)-AB and predrug, UV, or (R)-AB þ UV þ washout values (p < 0. 05, Student’s t test). Hash marks (#, C) indicate a
statistically significant difference in fraction of current available at-50mVbetween predrug andwashout values or betweenUVand (R)-þUV
þ washout values (p < 0. 05, Student’s t test). Data are from 7-12 cells per condition. The V1/2 (D, K) and k (E, L) of activation were not
different among any of the conditions tested (p > 0.05, one-way ANOVA). Similarly, the V1/2 (F, M) and k (G, N) of steady-state fast
inactivation were not different among any of the conditions tested (p > 0.05, one-way ANOVA).
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of Naþ channels remained in a slow-inactivated state, a
value nearly identical to that observed in cells exposed to
DMSO control or UV alone. This finding suggests that
photoactivationof (R)-7didnot lead to irreversible recep-
tor adduction. The current amplitudes at -10 mV in
cells treated with (R)-7, exposed to UV irradiation, and
thenwashed for 5min recoveredby87%comparedwith
the values in cells exposed to DMSO control or UV
alone. There were no changes in steady-state activation
or fast inactivation in any of the conditions tested
(Figure 11D-G).
Conclusions
Thedatavalidated that incorporating the selectedAB
and the CR groups in (R)-1 did not affect the ability of
these agents to induce Naþ slow inactivation processes
in CAD cells. Remarkably, we found that both (R)-2
and (R)-4 agents were more effective than (R)-1 in
promoting Naþ channel slow inactivation. This finding
may reflect that the lacosamideagents bind tighter to the
receptor(s) responsible for slow inactivation or is simply
a manifestation of their higher intracellular concentra-
tions. In this regard, incorporating AB and CR units
within the (R)-1 likely increases the lipophilicity of these
compounds over (R)-1 and perhaps increases their entry
into the cell. Finally, we obtained preliminary evidence
for modest permanent Naþ channel slow inactivation
upon treatment with either the electrophilic AB agent
(R)-5 or the photolabile AB (R)-6 after AB activation.
Our study did not allow us to address how (R)-1, (R)-2,
and (R)-4 affect Naþ channel slow inactivation. The
precise pathway for (R)-1modulation of Naþ channels
has not been revealed (21, 22). Thus, one possibility is
that (R)-1, (R)-2, and (R)-4bind to a segment of theNaþ
channel promoting slow-inactivation. Alternatively, (R)-1
and its derivatives may bind to another receptor(s) in
CAD cells that affects Naþ slow inactivation. These
questions remain central to our ongoing studies. We
expect that (R)-5, (R)-6, and (R)-8, as well as second
generation lacosamide AB and AB&CR agents that
provide higher levels of permanent Naþ channel slow





benzenemethanamine (10). Triphenylphosphine polymer
bound (Fluka, cat # 93094) (1.6 g/mol, 6.3 mmol) was added
to an aqueous (378 μL, 21.0mmol)/THF (10mL) solution of
3-[4-(azidomethyl)phenyl]-3-(trifluoromethyl)-3H-diazirine
(37) (11) (506 mg, 2.1 mmol). The mixture was shaken until
the starting material was no longer evident by TLC analysis
(18 h). The triphenylphosphine-based support was filtered
and washed with CH2Cl2, and the filtrate was concentrated
in vacuo to obtain 350 mg (80%) of a yellow oil correspond-
ing to the free amine: 1H NMR (CDCl3) δ 1.35-1.50 (br s,
NH2), 3.89 (s, CH2), 7.17 (d, J=8.2Hz, 2ArH), 7.35 (d, J=
8.2Hz, 2 ArH); 13CNMR (CDCl3) δ 28.4 (q, J=39.9 Hz,C
diazirine), 45.9 (CH2NH2), 122.2 (q, J = 273.2 Hz, CF3),
126.7, 127.5, 145.0 (4ArC), one signalwas not detected and is
believed to overlap with nearby peaks; HRMS (M þ Hþ)
(ESIþ) 216.0747 [MþHþ] (calcd forC9H8F3N3Hþ 216.0749).
The amine was stored and used as the hydrochloride salt.
Preparation of (R)-N-(4-(3-(Trifluoromethyl)-3H-diazirin-
3-yl)benzyl 2-Acetamido-3-methoxypropionamide ((R)-7). 4-[3-
(Trifluoromethyl)-3H-diazirin-3-yl]-benzenemethanamine
hydrochloride (10 3HCl) (933 mg, 3.7 mmol) was added to a
THF (31 mL) solution of the (R)-2-acetamido-3-methoxypro-
pionoic acid(36) ((R)-9) (500 mg, 3.1 mmol), and the mixture
was stirred at room temperature (5 min) and then NMM (0.41
mL, 3.7mmol) was added. Themixture was stirred a room tem-
perature (5 min), DMTMM (1.03 g, 3.7 mmol) was added, and
the mixture was again stirred at room temperature (16 h). The
white precipitatewas filtered, and the filtratewas concentrated in
vacuo. The residue was purified by flash column chromatogra-
phy on silica gel with EtOAc/acetone (10/0 to 6/4) as the eluant
to obtain a white solid (810 mg, 73%):Rf = 0.74 (EtOAc); mp
195 C (decomp); [R]25D -11.0 (c 0.5, CHCl3); IR (nujol)
3278, 1635, 1554, 1458, 1375, 1236, 1186, 1148, 1054, 940, 805,
731 cm-1; 1H NMR (CDCl3) δ 2.02 (s, CH3C(O)), 3.38
(s, OCH3), 3.44 (dd, J = 7.2, 9.0 Hz, CHH
0), 3.80 (dd, J =
4.2, 9.0 Hz, CHH0), 4.40-4.51 (m, CH2), 4.52-4.59 (m, CH),
6.45 (d, J=6.0Hz,NHC(O)CH3), 6.89-6.98 (br t, NHCH2),
7.15 (d, J = 8.2 Hz, 2 ArH), 7.29 (d, J = 8.2 Hz, 2 ArH),
addition of excess (R)-(-)-mandelic acid to a CDCl3 solution
of (R)-7 gave only one signal for the acetyl methyl and one
signal for the ether methyl protons; 13C NMR (CDCl3) δ 23.2
(CH3C(O)), 28.3 (q, J = 40.1 Hz, C diazirine), 43.0 (CH2N),
52.5 (CH), 59.1 (OCH3), 71.5 (CH2OCH3), 122.1 (q, J=273.1
Hz, CF3), 126.9, 127.8, 128.3, 139.9 (4 ArC), 170.2, 170.4
(2CO); HRMS (MþHþ) (ESIþ) 359.1334 [MþNaþ] (calcd
C15H17F3N4O3H
þ 359.1331). Anal. Calcd. for C15H17-
F3N4O3 3 0.05C3H6O: C, 50.34; H, 4.81; F, 15.83; N, 15.56.
Found: C, 50.59; H, 4.76; F, 15.46; N, 15.24.
Pharmacology
Compounds were screened under the auspices of the Na-
tional Institutes of Health’s Anticonvulsant Screening Pro-
gram. Experiments were performed in male rodents [albino
Carworth FarmsNo. 1mice (intraperitoneal route, ip), albino
Spague-Dawley rats (oral route, po)]. Housing, handling, and
feeding were in accordance with recommendations contained
in the Guide for the Care and Use of Laboratory Animals
(National Academies Press). Anticonvulsant activity was
established using the MES test(24) and the scMet test (44),
according to previously reported methods (16).
Catecholamine A Differentiated (CAD) Cells
CAD cells were grown at 37 C and in 5% CO2 (Sarstedt,
Newton,NC) inHam’sF12/EMEMmedium(GIBCO,Grand
Island, NY), supplemented with 8% fetal bovine serum (FBS;
Sigma, St. Louis,MO) and1%penicillin/streptomycin (100%
stocks, 10 000 U/mL penicillin G sodium and 10 000 μg/mL
streptomycin sulfate) (45, 46). Cells were passaged every 6-7
days at a 1:25 dilution.
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Quantitative Reverse Transcriptase PCR (qRT-PCR)
The mRNA levels of genes were quantitatively evaluated
by real-time qRT-PCR as described (54). Single-stranded
cDNA was synthesized from CAD cell RNA using reverse
transcriptase (Bioline) witholigo-dTprimers.For qRT-PCR,
resultant cDNA samples were amplified on anABI PRISM
7900HT Sequence Detection system (Applied Biosystems)
using SYBR Green as a reporter. In most cases, the PCR
reaction was run under the following conditions: 1, 50 C,
2 min; 1, 95 C, 10 min; 45, 95 C, 15 s, 60 C, 1 min; 1,
72 C, hold. To check whether amplification yielded PCR
products with a single molecular weight, the PCR products
were electrophoresed and sequenced. In addition, melting
curve analysis was performed to confirm the authenticity of
the PCR products. To check for DNA contamination, PCR
was run with cDNA samples by using an L27 (ribosomal
housekeeping gene) primer pair, whose PCR product crosses
an intron. To check the linearity of detection, a cDNA
dilution series (1, 1/10, 1/100, and 1/1000) was amplified
with gene-specific primer pairs, and a correlation coefficient
was calculated from the standard curve displaying threshold
cycles (Ct) asa functionof log10cDNAconcentrations (55,56).
The mRNA level for each gene (x) relative to L27 mRNA
(internal control) was calculated as follows: mRNA(x%)=
2Ct(L27)-Ct(x)  100.
Electrophysiology
Whole-cell voltage clamp recordingswere performedat room
temperature on CAD cells using an EPC 10 amplifier (HEKA
Electronics, Germany). Electrodes were pulled from thin-walled
borosilicate glass capillaries (Warner Instruments,Hamden,CT)
with a P-97 electrode puller (Sutter Instrument, Novato, CA)
such that final electrode resistances were 1-2 MΩ when filled
with internal solutions. The internal solution for recording Naþ
currents contained (in mM) 110 CsCl, 5 MgSO4, 10 EGTA,
4 ATPNa2-ATP, and 25 HEPES (pH 7.2, 290-310 mOsm/L).
The external solution contained (in mM) 100 NaCl, 10 tetra-
ethylammoniumchloride (TEA-Cl), 1CaCl2, 1CdCl2, 1MgCl2,
10 D-glucose, 4 4-AP, 0.1 NiCl2, and 10 HEPES (pH 7.3,
310-315 mOsm/L). Whole-cell capacitance and series resis-
tance were compensated with the amplifier. Series resistance
error was always compensated to be less than (3 mV. Cells
were considered only when the seal resistance was less than
3 MΩ. Linear leak currents were digitally subtracted by P/4.
Lacosamide AB Modification Studies
For experiments designed to determine if lacosamide AB
derivatives interacted in a reversible or irreversible manner to
affect slow inactivation, the agents (details of concentrations
provided in the figure legends) were applied to the CAD cells
for 10 min at 37 C and then washed three times for a total of
5 min at 37 C prior to whole-cell electrophysiology. The
washes (2 mL each) were performed using complete Ham’s
F12/EMEM medium. Cells were incubated at 37 C during
the washes. Following this washing regimen, the cells were
placed in 0.5 mL of extracellular bathing solution for up to
3 min prior to establishing recording seals.
Data Acquisition and Analysis
Signals were filtered at 10 kHz and digitized at 10-20 kHz.
Analysis was performed using Fitmaster and origin8.1
(OriginLabCorporation,Northampton,MA). For activation
curves, conductance (G) throughNaþ channelswas calculated
using the equation G = I/(Vm - Vrev), where Vrev is the
reversal potential, Vm is the membrane potential at which the
currentwas recorded, and I is the peak current.Activation and
inactivation curves were fitted to a single-phase Boltzmann
function G/Gmax = 1/{1 þ exp[(V - V50)/k]}, where G is the
peak conductance,Gmax is the fittedmaximalG,V50 is the half
activation voltage, and k is the slope factor. Additional details
of specific pulse protocols are described in the results text or
figure legends.
Statistical Analyses
Differences between means were compared by unpaired,
two-tailed Student’s t tests or an analysis of variance
(ANOVA), when comparing multiple groups (repeated mea-
sures whenever possible). If a significant difference is deter-
mined by ANOVA, then a Dunnett’s or Tukey’s posthoc test
was performed.Data are expressed asmean( SEM,with p<
0.05 considered as the level of significance.
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